Medtronic to pay Etex breach of contract damages
This article was originally published in The Gray Sheet
Executive Summary
California arbitrator forces Medtronic to shell out $50.2 mil., plus interest, to Etex for retracting its 2002 agreement to purchase the firm contingent upon the development of a bone graft product meeting certain technical specifications. Medtronic claimed the product failed to meet the agreed specifications. The arbitrator disputed Etex' allegations of antitrust, fraud and tort claims against Medtronic, whose minority interest in Etex is unaltered by the decision. Medtronic will record a charge in fiscal Q4 related to the ruling...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.